ABSTRACT Enhancing therapeutic efficacy while reducing toxicity is a central objective of cancer treatment, and the precise, synchronous activation of combination therapies represents an effective strategy to address this issue. Herein, we design a heterobimetallic prodrug ( LM‐RCu ) platform that enables in situ synthesis of cytotoxic copper (Cu) complex with concurrent activation of metal‐based photosensitizer via intramolecular transmetalation to achieve tumor‐targeted chemo‐photodynamic‐immunotherapy. The general LM‐RCu contains a stimuli‐responsive diethyldithiocarbamate ( DTC ) prochelator, a quenched Ru/Ir/Os‐based photosensitizer (“OFF” state), and a DPA‐Cu moiety, which skillfully acts as both Cu 2+ reservoir for DTC and quencher for photosensitizers. Upon tumor‐specific stimulation, structurally tunable LM‐RCu releases DTC, which chelates Cu 2+ from intramolecular DPA‐Cu to in situ synthesize cytotoxic Cu(DTC) 2 complex, while dissociation of DPA‐Cu simultaneously activates photosensitizer (“ON” state). Representatively, the heterobimetallic Ru‐Cu prodrug bRu‐BCu is selectively triggered by tumor‐elevated ROS to generate Cu(DTC) 2 and synchronously activate Ru‐based photosensitizer. Upon light irradiation, the activated photosensitizer produces type I/II ROS for cells killing while promoting more DTC release, thereby driving the self‐boosting loop of Cu(DTC) 2 generation and photosensitizer activation, inducing immunogenic PANoptosis to stimulate potent immune responses against primary/distant tumors with minimal toxicity. Overall, this universal and versatile prodrug platform provides an innovative strategy for precise and effective cancer therapy.
Huang et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: